Clinical tests of platelet function

Platelets

Volumn , Issue , 2007, Pages 445-474

  Harrison, Paul ^a   Keeling, David ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33751095590     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369367-9/50785-0     Document Type: Chapter

References (248)

1. George J.N. Platelets. Lancet 2000, 355:1531-1539.
2. The British Society for Haematology (BCSH) Haemostasis, Thrombosis Task Force. Guidelines on platelet function testing. J Clin Pathol 1988, 41:1322-1330.
3. Gawaz M., Langer H., May A.E. Platelets in inflammation and atherogenesis. J Clin Invest 2005, 115:3378-3384.
4. Ruggeri Z.M. Platelets in atherothrombosis. Nat Med 2002, 8:1227-1234.
5. Harrison P. Platelet function analysis. Blood Rev 2005, 19:111-123.
6. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000, 111:733-744.
7. de Gaetano G. A new blood corpuscle: An impossible interview with Giulio Bizzozero. Thromb Haemost 2001, 86:973-979.
8. Brecher G., Cronkite E.P. Morphology and enumeration of human blood platelets. J Appl Physiol 1950, 3:365-377.
9. Brecher G., Schneiderman M., Cronkite E.P. The reproducibility and constancy of the platelet count. Am J Clin Pathol 1953, 23:15-26.
10. Coulter W.H. Means for counting particles suspended in a fluid 1953, US patent no. 2,656,508.
11. Harrison P., Briggs C., Machin S.J. Platelet counting. Methods Mol Biol 2004, 272:29-46.
12. Mundschenk D.D., Connelly D.P., White J.G., et al. An improved technique for the electronic measurement of platelet size and shape. J Lab Clin Med 1976, 88:301-315.
13. Bull B.S., Schneiderman M.A., Brecher G. Platelet counts with the Coulter counter. Am J Clin Pathol 1965, 44:678-688.
14. Bessman J.D., Williams L.J., Gilmer P.R. Mean platelet volume. The inverse relation of platelet size and count in normal subjects, and an artifact of other particles. Am J Clin Pathol 1981, 76:289-293.
15. Kunicka J.E., Fischer G., Murphy J., et al. Improved platelet counting using two-dimensional laser light scatter. Am J Clin Pathol 2000, 114:283-289.
16. Harrison P., Ault K.A., Chapman S., et al. An interlaboratory study of a candidate reference method for platelet counting. Am J Clin Pathol 2001, 115:448-459.
17. Harrison P., Segal H., Briggs C., et al. Impact of immunological platelet counting (by the platelet/RBC ratio) on haematological practice. Cytom B Clin Cytom 2005, 67:1-5.
18. Duke W.W. The relation of blood platelets to hemorrhagic disease. Description of a method for determining the bleeding time and the coagulation time and report of three cases of hemorrhagic disease relieved by blood transfusion. JAMA 1910, 55:1185-1192.
19. Harker L.A., Slichter S.J. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med 1972, 287:155-159.
20. Nilsson I.M., Magnusson S., Borchgrevink C. The Duke and Ivy methods for determination of the bleeding time. Thromb Diath Haemorrh 1963, 10:223-234.
21. Rodgers R.P., Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990, 16:1-20.
22. Lind S.E. The bleeding time does not predict surgical bleeding. Blood 1991, 77:2547-2552.
23. Peterson P., Hayes T.E., Arkin C.F., et al. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. Arch Surg 1998, 133:134-139.
24. Born G.V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962, 194:927-929.
25. O'Brien J.M. Platelet aggregation. II. Some results from a new method of study. J Clin Pathol 1962, 15:452-481.
26. Zhou L., Schmaier A.H. Platelet aggregation testing in platelet-rich plasma: Description of procedures with the aim to develop standards in the field. Am J Clin Pathol 2005, 123:172-183.
27. Moffat K.A., Ledford-Kraemer M.R., Nichols W.L., et al. Variability in clinical laboratory practice in testing for disorders of platelet function: Results of two surveys of the North American Specialized Coagulation Laboratory Association. Thromb Haemost 2005, 93:549-553.
28. Cardinal D.C., Flower R.J. The electronic aggregometer: A novel device for assessing platelet behavior in blood. J Pharmacol Methods 1980, 3:135-158.
29. Smith J.W., Steinhubl S.R., Lincoff A.M., et al. Rapid platelet-function assay: An automated and quantitative cartridge-based method. Circulation 1999, 99:620-625.
30. Kereiakes D.J., Mueller M., Howard W., et al. Efficacy of abciximab induced platelet blockade using a rapid point of care assay. J Thromb Thrombolysis 1999, 7:265-276.
31. Coller B.S., Lang D., Scudder L.E. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation 1997, 95:860-867.
32. Fox S.C., Burgess-Wilson M., Heptinstall S., et al. Platelet aggregation in whole blood determined using the Ultra-Flo 100 Platelet Counter. Thromb Haemost 1982, 48:327-329.
33. Heptinstall S., Fox S., Crawford J., et al. Inhibition of platelet aggregation in whole blood by dipyridamole and aspirin. Thromb Res 1986, 42:215-223.
34. Glenn R., White A.E., Johnson A., et al. Leukocyte count and leukocyte ecto-nucleotidase are major determinants of the effects of adenosine triphosphate and adenosine diphosphate on platelet aggregation in human blood. Platelets 2005, 16:159-170.
35. Carville D.G., Schleckser P.A., Guyer K.E., et al. Whole blood platelet function assay on the ICHOR point-ofcare hematology analyzer. J Extra Corpor Technol 1998, 30:171-177.
36. Craft R.M., Chavez J.J., Snider C.C., et al. Comparison of modified thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J Lab Clin Med 2005, 145:309-315.
37. White M.M., Krishnan R., Kueter T.J., et al. The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPFA for assessment of platelet function with GPIIB-IIIa antagonists. J Thromb Thrombolysis 2004, 18:163-169.
38. Lennon M.J., Gibbs N.M., Weightman W.M, et al. A comparison of Plateletworks and platelet aggregometry for the assessment of aspirin-related platelet dysfunction in cardiac surgical patients. J Cardiothorac Vasc Anesth 2004, 18:136-140.
39. Nicholson N.S., Panzer-Knodle S.G., Haas N.F., et al. Assessment of platelet function assays. Am Heart J 1998, 135:S170-S178.
40. Mobley J.E., Bresee S.J., Wortham D.C., et al. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol 2004, 93:456-458.
41. Lakkis N.M., George S., Thomas E., et al. Use of ICHOR/Plateletworks to assess platelet function in patients treated with GP IIb/IIIa inhibitors. Catheter Cardiovasc Interv 2001, 53:346-351.
42. Wu K.K., Hoak J.C. A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet 1974, ii:924-926.
43. Grotemeyer K.H. The platelet reactivity test: A useful "by-product" of the blood-sampling procedure?. Thromb Res 1991, 61:423-431.
44. Koscielny J., Meyer O., Kiesewetter H., et al. [Platelet reactivity index by Grotemeyer.]. Hamostaseologie 2004, 24:207-210.
45. Hellem A.J. The adhesiveness of human blood platelets in vitro. Scand J Clin Lab Invest 1960, 12:1-117. (suppl).
46. O'Brien J.R., Etherington M.D. Antiglycoprotein Ib causes platelet aggregation: Different effects of blocking glycoprotein Ib and glycoprotein IIb/IIIa in the high shear filterometer. Blood Coagul Fibrinolysis 1998, 9:453-461.
47. O'Brien J.R., Salmon G.P. Shear stress activation of platelet glycoprotein IIb/IIIa plus von Willebrand factor causes aggregation: Filter blockage and the long bleeding time in von Willebrand's disease. Blood 1987, 70:1354-1361.
48. Krischek B., Morgenstern E., Mestres P., et al. Adhesion, spreading, and aggregation of platelets in flowing blood and the reliability of the retention test Homburg. Semin Thromb Hemost 2005, 31:449-457.
49. Krischek B., Brannath W., Klinkhardt U., et al. Role of the retention test Homburg in evaluating platelet hyperactivity and in monitoring therapy with antiplatelet drugs. Semin Thromb Hemost 2005, 31:458-463.
50. Nowak G., Wiesenburg A., Schumann A., et al. Platelet adhesion assay: A new quantitative whole blood test to measure platelet function. Semin Thromb Hemost 2005, 31:470-475.
51. Falati S., Gross P.L., Merrill-Skoloff G., et al. In vivo models of platelet function and thrombosis: Study of real-time thrombus formation. Methods Mol Biol 2004, 272:187-197.
52. Falati S., Gross P., Merrill-Skoloff G., et al. Realtime in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med 2002, 8:1175-1181.
53. Furie B., Furie B.C. Thrombus formation in vivo. J Clin Invest 2005, 115:3355-3362.
54. Gorog D.A., Kovacs I.B. Thrombotic status analyser. Measurement of platelet-rich thrombus formation and lysis in native blood. Thromb Haemost 1995, 73:514-520.
55. Li C.K., Hoffmann T.J., Hsieh P.Y., et al. The Xylum Clot Signature Analyzer: A dynamic flow system that simulates vascular injury. Thromb Res 1998, 92:S67-S77.
56. Fricke W., Kouides P., Kessler C., et al. A multicenter clinical evaluation of the Clot Signature Analyzer. J Thromb Haemost 2004, 2:763-768.
57. Gorog P., Ahmed A. Haemostatometer: A new in vitro technique for assessing haemostatic activity of blood. Thromb Res 1984, 34:341-357.
58. Yamamoto J., Yamashita T., Ikarugi H., et al. Gorog thrombosis test: A global in-vitro test of platelet function and thrombolysis. Blood Coagul Fibrinolysis 2003, 14:31-39.
59. Spectre G., Brill A., Gural A., et al. A new pointofcare method for monitoring anti-platelet therapy: Application of the cone and plate(let) analyzer. Platelets 2005, 16:293-299.
60. Kenet G., Lubetsky A., Shenkman B., et al. Cone and platelet analyser (CPA): A new test for the prediction of bleeding among thrombocytopenic patients. Br J Haematol 1998, 101:255-259.
61. Varon D., Lashevski I., Brenner B., et al. Cone and plate (let) analyzer: Monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. Am Heart J 1998, 135:S187-S193.
62. Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol 2005, 130:3-10.
63. Jilma B. Platelet function analyzer (PFA-100): A tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001, 138:152-163.
64. Kundu S.K., Heilmann E.J., Sio R., et al. Characterization of an in vitro platelet function analyzer: PFA-100. Clin Appl Thromb Hemost 1996, 2:241-249.
65. Kundu S.K., Heilmann E.J., Sio R., et al. Description of an in vitro platelet function analyzer: PFA-100. Semin Thromb Hemost 1995, 21(suppl 2):106-112.
66. Caen J.P., Rosa J.P. Platelet-vessel wall interaction: From the bedside to molecules. Thromb Haemost 1995, 74:18-24.
67. Gerotziafas G.T., Depasse F., Busson J., et al. Towards a standardization of thrombin generation assessment: The influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay. Thromb J 2005, 3:16.
68. Al D.R., Peyvandi F., Santagostino E., et al. The thrombogram in rare inherited coagulation disorders: Its relation to clinical bleeding. Thromb Haemost 2002, 88:576-582.
69. Hemker H.C., Beguin S. Thrombin generation in plasma: Its assessment via the endogenous thrombin potential. Thromb Haemost 1995, 74:134-138.
70. Coiffic A., Cazes E., Janvier G., et al. Inhibition of platelet aggregation by abciximab but not by aspirin can be detected by a new point-of-care test, the hemostatus. Thromb Res 1999, 95:83-91.
71. Despotis G.J., Levine V., Saleem R., et al. Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: A randomised controlled trial. Lancet 1999, 354:106-110.
72. Despotis G.J., Levine V., Filos K.S., et al. Evaluation of a new point-of-care test that measures PAF-mediated acceleration of coagulation in cardiac surgical patients. Anesthesiology 1996, 85:1311-1323.
73. Luddington R.J. Thromboelastography/thromboelastometry. Clin Lab Haematol 2005, 27:81-90.
74. Salooja N., Perry D.J. Thromboelastography. Blood Coagul Fibrinolysis 2001, 12:327-337.
75. Hartert H. Thromboelastography, a method for physical analysis of blood coagulation. Z Gesamte Exp Med 1951, 117:189-203.
76. Lang T., Bauters A., Braun S.L., et al. Multicentre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis 2005, 16:301-310.
77. Tantry U.S., Bliden K.P., Gurbel P.A. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005, 46:1705-1709.
78. Bowbrick V.A., Mikhailidis D.P., Stansby G. Value of thromboelastography in the assessment of platelet function. Clin Appl Thromb Hemost 2003, 9:137-142.
79. Hett D.A., Walker D., Pilkington S.N., et al. Sonoclot analysis. Br J Anaesth 1995, 75:771-776.
80. LaForce W.R., Brudno D.S., Kanto W.P., et al. Evaluation of the Sono Clot Analyzer for the measurement of platelet function in whole blood. Ann Clin Lab Sci 1992, 22:30-33.
81. Chandler W.L., Schmer G. Evaluation of a new dynamic viscometer for measuring the viscosity of whole blood and plasma. Clin Chem 1986, 32:505-507.
82. Carr M.E., Zekert S.L. Measurement of platelet-mediated force development during plasma clot formation. Am J Med Sci 1991, 302:13-18.
83. Carr M.E., Martin E.J., Kuhn J.G., et al. Onset of force development as a marker of thrombin generation in whole blood: The thrombin generation time (TGT). J Thromb Haemost 2003, 1:1977-1983.
84. Carr M.E.Jr. Development of platelet contractile force as a research and clinical measure of platelet function. Cell Biochem Biophys 2003, 38:55-78.
85. Carr M.E.Jr. Measurement of platelet force: The Hemodyne hemostasis analyzer. Clin Lab Manage Rev 1995, 9:312-318.
86. Carr M.E.Jr. Measurement of platelet force: The Hemodyne hemostasis analyzer. Clin Lab Manage Rev 1995, 9:320.
87. Michelson A.D., Furman M.I. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol 1999, 6:342-348.
88. Schmitz G., Rothe G., Ruf A., et al. European Working Group on clinical cell analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998, 79:885-896.
89. Michelson A.D. Flow cytometry: A clinical test of platelet function. Blood 1996, 87:4925-4936.
90. Francis J.L., Francis D., Larson L., et al. Can the platelet function analyser (PFA-100) substitute for the bleeding time in routine clinical practice. Platelets 1999, 10:132-136.
91. Hayward C.P., Harrison P., Cattaneo M., et al. Platelet function analyser (PFA-100) closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006, 4:1-8.
92. Nieuwenhuis H.K., Akkerman J.W., Sixma J.J. Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: Studies on 106 patients. Blood 1987, 70:620-623.
93. Israels S.J., McNicol A., Robertson C., et al. Platelet storage pool deficiency: Diagnosis in patients with prolonged bleeding times and normal platelet aggregation. Br J Haematol 1990, 75:118-121.
94. Wall J.E., Buijs-Wilts M., Arnold J.T., et al. A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents. Br J Haematol 1995, 89:380-385.
95. Gordon N., Thom J., Cole C., et al. Rapid detection of hereditary and acquired platelet storage pool deficiency by flow cytometry. Br J Haematol 1995, 89:117-123.
96. White M.M., Foust J.T., Mauer A.M., et al. Assessment of lumiaggregometry for research and clinical laboratories. Thromb Haemost 1992, 67:572-577.
97. Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost 2003, 1:1628-1636.
98. Linden M.D., Frelinger A.L., Barnard M.R., et al. Application of flow cytometry to platelet disorders. Semin Thromb Hemost 2004, 30:501-511.
99. Cattaneo M., Zighetti M.L., Lombardi R., et al. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci U S A 2003, 100:1978-1983.
100. Mazurov A.V., Vinogradov D.V., Khaspekova S.G., et al. Deficiency of P-selectin in a patient with grey platelet syndrome. Eur J Haematol 1996, 57:38-41.
101. McNicol A., Israels S.J., Robertson C., et al. The empty sack syndrome: A platelet storage pool deficiency associated with empty dense granules. Br J Haematol 1994, 86:574-582.
102. Solum N.O. Procoagulant expression in platelets and defects leading to clinical disorders. Arterioscler Thromb Vasc Biol 1999, 19:2841-2846.
103. Horstman L.L., Ahn Y.S. Platelet microparticles: A wide-angle perspective. Crit Rev Oncol Hematol 1999, 30:111-142.
104. White J.G. Electron microscopy methods for studying platelet structure and function. Methods Mol Biol 2004, 272:47-63.
105. Michelson A.D. Platelet function testing in cardiovascular diseases. Circulation 2004, 110:e489-e493.
106. Cattaneo M. Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004, 24:1980-1987.
107. Michelson A.D., Cattaneo M., Eikelboom J.W., et al. Aspirin resistance: Position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005, 3:1309-1311.
108. Szczeklik A., Musial J., Undas A., et al. Aspirin resistance. J Thromb Haemost 2005, 3:1655-1662.
109. Roth G.J., Majerus P.W. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975, 56:624-632.
110. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86.
111. Rocca B., Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 2005, 3:1597-1602.
112. Schwartz K.A., Schwartz D.E., Ghosheh K., et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005, 95:973-975.
113. Weber A.A., Przytulski B., Schanz A., et al. Towards a definition of aspirin resistance: A typological approach. Platelets 2002, 13:37-40.
114. Homoncik M., Jilma B., Hergovich N., et al. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000, 83:316-321.
115. Feuring M., Schultz A., Losel R., et al. Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100. Semin Thromb Hemost 2005, 31:411-415.
116. Andersen K., Hurlen M., Arnesen H., et al. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002, 108:37-42.
117. Sambola A., Heras M., Escolar G., et al. The PFA-100 detects sub-optimal antiplatelet responses in patients on aspirin. Platelets 2004, 15:439-446.
118. Coakley M., Self R., Marchant W., et al. Use of the platelet function analyser (PFA-100) to quantify the effect of low dose aspirin in patients with ischaemic heart disease. Anaesthesia 2005, 60:1173-1178.
119. Coma-Canella I., Velasco A., Castano S. Prevalence of aspirin resistance measured by PFA-100. Int J Cardiol 2005, 101:71-76.
120. Peters A.J., Borries M., Gradaus F., et al. Vitro bleeding test with PFA-100-aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease. J Thromb Thrombolysis 2001, 12:263-272.
121. Harrison P., Mackie I., Mathur A., et al. Platelet hyper-function in acute coronary syndromes. Blood Coagul Fibrinolysis 2005, 16:557-562.
122. McCabe D.J., Harrison P., Mackie I.J., et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets 2005, 16:269-280.
123. Alberts M.J., Bergman D.L., Molner E., et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004, 35:175-178.
124. Chakroun T., Gerotziafas G., Robert F., et al. Vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol 2004, 124:80-85.
125. Frossard M., Fuchs I., Leitner J.M., et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004, 110:1392-1397.
126. Macchi L., Christiaens L., Brabant S., et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002, 107:45-49.
127. Harrison P., Segal H., Blasbery K., et al. Screening for aspirin responsiveness after transient ischemic attack and stroke: Comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005, 36:1001-1005.
128. Gum P.A., Kottke-Marchant K., Poggio E.D., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001, 88:230-235.
129. Gum P.A., Kottke-Marchant K., Welsh P.A., et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003, 41:961-965.
130. Steinhubl S.R., Varanasi J.S., Goldberg L. Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003, 42:1336-1337.
131. Jilma B. Therapeutic failure or resistance to aspirin. J Am Coll Cardiol 2004, 43:1332-1333.
132. Eikelboom J.W., Hankey G.J. Aspirin resistance: A new independent predictor of vascular events?. J Am Coll Cardiol 2003, 41:966-968.
133. Grundmann K., Jaschonek K., Kleine B., et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003, 250:63-66.
134. Lanza G.A., Sestito A., Iacovella S., et al. Relation between platelet response to exercise and coronary angiographic findings in patients with effort angina. Circulation 2003, 107:1378-1382.
135. Fuchs I., Frossard M., Spiel A., et al. Platelet hyperfunction and low response to aspirin predict re-events in patients with acute coronary syndromes during long term follow up. J Thromb Haemost 2005, 3(suppl 1). abstract 2142.
136. Christie D.J., Kottke-Marchant K., Gorman R. High shear platelet function is associated with major adverse events in patients with stable cardiovascular disease (CVD) despite aspirin therapy. J Thromb Haemost 2005, 3(suppl 1). abstract 2204.
137. Application of cationic propyl gallate as inducer of thrombocyte aggregation for evaluation of effectiveness of antiaggregation therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2001, 145:69-74.
138. Malinin A., Spergling M., Muhlestein B., et al. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 2004, 15:295-301.
139. Wang J.C., Aucoin-Barry D., Manuelian D., et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 2003, 92:1492-1494.
140. Chen W.H., Lee P.Y., Ng W., et al. Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention. Am J Cardiol 2005, 96:760-763.
141. Chen W.H., Lee P.Y., Ng W., et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004, 43:1122-1126.
142. Lee P.Y., Chen W.H., Ng W., et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005, 118:723-727.
143. Eikelboom J.W., Hirsh J., Weitz J.I., et al. Aspirinresistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002, 105:1650-1655.
144. Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 2006, 46:277-300.
145. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329-1339.
146. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by longterm therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001, 358:527-533.
147. Diener H.C., Bogousslavsky J., Brass L.M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 2004, 364:331-337.
148. Savi P., Herbert J.M. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005, 31:174-183.
149. Serebruany V.L., Steinhubl S.R., Berger P.B., et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005, 45:246-251.
150. Nguyen T.A., Diodati J.G., Pharand C. Resistance to clopidogrel: A review of the evidence. J Am Coll Cardiol 2005, 45:1157-1164.
151. Gurbel P.A., Bliden K.P., Hiatt B.L., et al. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003, 107:2908-2913.
152. Jaremo P., Lindahl T.L., Fransson S.G., et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002, 252:233-238.
153. Lau W.C., Gurbel P.A., Watkins P.B., et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004, 109:166-171.
154. Michelson A.D., Linden M.D., Furman M.I., et al. Pre-existent variability in platelet response to ADP accounts for clopidogrel resistance. J Thromb Haemost 2005, 3(suppl 1). abstract P0955.
155. Geiger J., Teichmann L., Grossmann R., et al. Monitoring of clopidogrel action: Comparison of methods. Clin Chem 2005, 51:957-965.
156. Gurbel P.A., Bliden K.P., Hayes K.M., et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005, 45:1392-1396.
157. Muller I., Seyfarth M., Rudiger S., et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001, 85:92-93.
158. Gurbel P.A., Bliden K.P., Zaman K.A., et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: Results of the Clopidogrel Loading with Epti-fibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005, 111:1153-1159.
159. Aleil B., Ravanat C., Cazenave J.P., et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005, 3:85-92.
160. Matetzky S., Shenkman B., Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004, 109:3171-3175.
161. Fox S.C., Behan M.W., Heptinstall S. Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists ARC69931MX and clopidogrel is enhanced by prostaglandin E1. Cell Calcium 2004, 35:39-46.
162. Gachet C., Cazenave J.P., Ohlmann P., et al. The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1. Biochem Pharmacol 1990, 40:2683-2687.
163. Barragan P., Bouvier J.L., Roquebert P.O., et al. Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003, 59:295-302.
164. Golanski J., Pluta J., Baraniak J., et al. Limited usefulness of the PFA-100 for the monitoring of ADP receptor antagonists: In vitro experience. Clin Chem Lab Med 2004, 42:25-29.
165. Mueller T., Haltmayer M., Poelz W., et al. Monitoring aspirin 100 mg and clopidogrel 75 mg therapy with the PFA-100 device in patients with peripheral arterial disease. Vasc Endovasc Surg 2003, 37:117-123.
166. Ziegler S., Maca T., Alt E., et al. Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients. Platelets 2002, 13:493-497.
167. Raman S., Jilma B. Time lag in platelet function inhibition by clopidogrel in stroke patients as measured by PFA-100. J Thromb Haemost 2004, 2:2278-2279.
168. Jilma B. Synergistic antiplatelet effects of clopidogrel and aspirin detected with the PFA-100 in stroke patients. Stroke 2003, 34:849-854.
169. Gurbel P.A., Bliden K.P., Samara W., et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST Study. J Am Coll Cardiol 2005, 46:1827-1832.
170. Muller I., Besta F., Schulz C., et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003, 89:783-787.
171. Coller B.S., Folts J.D., Smith S.R., et al. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation 1989, 80:1766-1774.
172. Gold H.K., Coller B.S., Yasuda T., et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 1988, 77:670-677.
173. Thompson C.M., Steinhubl S.R. Monitoring of platelet function in the setting of GPIIb/IIIa inhibitor therapy. Curr Interv Cardiol Rep 1999, 1:270-277.
174. Wheeler G.L., Braden G.A., Steinhubl S.R., et al. The Ultegra rapid platelet-function assay: Comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J 2002, 143:602-611.
175. Simon D.I., Liu C.B., Ganz P., et al. A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofi ban. Catheter Cardiovasc Interv 2001, 52:425-432.
176. Steinhubl S.R., Talley J.D., Braden G.A., et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001, 103:2572-2578.
177. Hezard N., Metz D., Nazeyrollas P., et al. Use of the PFA-100 apparatus to assess platelet function in patients undergoing PTCA during and after infusion of c7E3 Fab in the presence of other antiplatelet agents. Thromb Haemost 2000, 83:540-544.
178. Madan M., Berkowitz S.D., Christie D.J., et al. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Am Heart J 2001, 141:226-233.
179. Madan M., Berkowitz S.D., Christie D.J., et al. Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. Am Heart J 2002, 144:151-158.
180. Koscielny J., Ziemer S., Radtke H., et al. A practical concept for preoperative identification of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004, 10:195-204.
181. Koscielny J., von Tempelhoff G.F., Ziemer S., et al. A practical concept for preoperative management of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004, 10:155-166.
182. Koh M.B., Hunt B.J. The management of perioperative bleeding. Blood Rev 2003, 17:179-185.
183. De Moerloose P. Laboratory evaluation of hemostasis before cardiac operations. Ann Thorac Surg 1996, 62:1921-1925.
184. Prisco D. and Paniccia R., Point-of-care testing of hemostasis in cardiac surgery. Thromb J, 1, pp. 1.
185. Mallett S.V., Cox D.J. Thrombelastography. Br J Anaesth 1992, 69:307-313.
186. Caprini J.A., Traverso C.I., Arcelus J.I. Perspectives on thromboelastography. Semin Thromb Hemost 1995, 21(suppl 4):91-93.
187. Shore-Lesserson L. Evidence based coagulation monitors: Heparin monitoring, thromboelastography, and platelet function. Semin Cardiothorac Vasc Anesth 2005, 9:41-52.
188. Shore-Lesserson L., Manspeizer H.E., DePerio M., et al. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999, 88:312-319.
189. Spiess B.D. Thromboelastography and cardiopulmonary bypass. Semin Thromb Hemost 1995, 21(suppl 4):27-33.
190. Nuttall G.A., Oliver W.C., Santrach P.J., et al. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology 2001, 94:773-781.
191. Royston D., von Kier S. Reduced haemostatic factor transfusion using heparinase-modified thromboelastography during cardiopulmonary bypass. Br J Anaesth 2001, 86:575-578.
192. Despotis G.J., Joist J.H., Goodnough L.T. Monitoring of hemostasis in cardiac surgical patients: Impact of point-of-care testing on blood loss and transfusion outcomes. Clin Chem 1997, 43:1684-1696.
193. Avidan M.S., Alcock E.L., Da Fonseca J., et al. Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgment in the management of bleeding after cardiac surgery. Br J Anaesth 2004, 92:178-186.
194. Poston R., Gu J., Manchio J., et al. Platelet function tests predict bleeding and thrombotic events after off-pump coronary bypass grafting. Eur J Cardiothorac Surg 2005, 27:584-591.
195. Ostrowsky J., Foes J., Warchol M., et al. Plateletworks platelet function test compared to the thromboelastograph for prediction of postoperative outcomes. J Extra Corpor Technol 2004, 36:149-152.
196. Hertfelder H.J., Bos M., Weber D., et al. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting. Semin Thromb Hemost 2005, 31:426-440.
197. Forestier F., Coiffic A., Mouton C., et al. Platelet function point-of-care tests in post-bypass cardiac surgery: Are they relevant?. Br J Anaesth 2002, 89:715-721.
198. Fattorutto M., Pradier O., Schmartz D., et al. Does the platelet function analyser (PFA-100) predict blood loss after cardiopulmonary bypass?. Br J Anaesth 2003, 90:692-693.
199. Elwood P.C., Beswick A., Pickering J., et al. Platelet tests in the prediction of myocardial infarction and ischaemic stroke: Evidence from the Caerphilly Prospective Study. Br J Haematol 2001, 113:514-520.
200. Thaulow E., Erikssen J., Sandvik L., et al. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991, 84:613-617.
201. Trip M.D., Cats V.M., van Capelle F.J., et al. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990, 322:1549-1554.
202. Meade T.W., Cooper J.A., Miller G.J. Platelet counts and aggregation measures in the incidence of ischaemic heart disease (IHD). Thromb Haemost 1997, 78:926-929.
203. Elwood P.C., Renaud S., Beswick A.D., et al. Platelet aggregation and incident ischaemic heart disease in the Caerphilly cohort. Heart 1998, 80:578-582.
204. Elwood P.C., Renaud S., Sharp D.S., et al. Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study. Circulation 1991, 83:38-44.
205. Kristensen S.D., Bath P.M., Martin J.F. Differences in bleeding time, aspirin sensitivity and adrenaline between acute myocardial infarction and unstable angina. Cardiovasc Res 1990, 24:19-23.
206. Martin J.F., Bath P.M., Burr M.L. Influence of platelet size on outcome after myocardial infarction. Lancet 1991, 338:1409-1411.
207. Elwood C., Pickering J., Yarnell J., et al. Bleeding time, stroke and myocardial infarction: The Caerphilly prospective study. Platelets 2003, 14:139-141.
208. Mammen E.F. Sticky platelet syndrome. Semin Thromb Hemost 1999, 25:361-365.
209. Mammen E.F., Barnhart M.I., Selik N.R., et al. "Sticky platelet syndrome": A congenital platelet abnormality predisposing to thrombosis?. Folia Haematol Int Mag Klin Morphol Blutforsch 1988, 115:361-365.
210. Yee D.L., Sun C.W., Bergeron A.L., et al. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 2005, 106:2723-2729.
211. Ault K.A., Cannon C.P., Mitchell J., et al. Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial. Thrombolysis in myocardial infarction. J Am Coll Cardiol 1999, 33:634-639.
212. Cardigan R., Turner C., Harrison P. Current methods of assessing platelet function: Relevance to transfusion medicine. Vox Sang 2005, 88:153-163.
213. Harrison P., Segal H., Furtado C., et al. High incidence of defective high-shear platelet function among platelet donors. Transfusion 2004, 44:764-770.
214. Jilma-Stohlawetz P., Hergovich N., Homoncik M., et al. Impaired platelet function among platelet donors. Thromb Haemost 2001, 86:880-886.
215. Borzini P., Lazzaro A., Mazzucco L. Evaluation of the hemostatic function of stored platelet concentrates using the platelet function analyzer (PFA-100). Haematologica 1999, 84:1104-1109.
216. Hoffmeister K.M., Josefsson E.C., Isaac N.A., et al. Glycosylation restores survival of chilled blood platelets. Science 2003, 301:1531-1534.
217. Segal H.C., Briggs C., Kunka S., et al. Accuracy of platelet counting haematology analysers in severe thrombocytopenia and potential impact on platelet transfusion. Br J Haematol 2005, 128:520-525.
218. Salama M.E., Raman S., Drew M.J., et al. Platelet function testing to assess effectiveness of platelet transfusion therapy. Transfus Apheresis Sci 2004, 30:93-100.
219. Favaloro E.J., Kershaw G., Bukuya M., et al. Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: Efficacy of the PFA-100 and vWF:CBA as combined diagnostic strategies. Haemophilia 2001, 7:180-189.
220. Fressinaud E., Veyradier A., Truchaud F., et al. Screening for von Willebrand disease with a new analyzer using high shear stress: A study of 60 cases. Blood 1998, 91:1325-1331.
221. Fressinaud E., Veyradier A., Sigaud M., et al. Therapeutic monitoring of von Willebrand disease: Interest and limits of a platelet function analyser at high shear rates. Br J Haematol 1999, 106:777-783.
222. Cattaneo M., Federici A.B., Lecchi A., et al. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999, 82:35-39.
223. Cattaneo M., Lecchi A., Agati B., et al. Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion. Thromb Res 1999, 96:213-217.
224. Reiter R.A., Mayr F., Blazicek H., et al. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 2003, 102:4594-4599.
225. Ghorashian S., Hunt B.J. Off-license" use of recombinant activated factor VII. Blood Rev 2004, 18:245-259.
226. Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev 2003, 17(suppl 1):S1-S5.
227. Hoffman M., Monroe D.M., Roberts H.R. Platelet-dependent action of high-dose factor VIIa. Blood 2002, 100:364-365.
228. Kjalke M., Johannessen M., Hedner U. Effect of recombinant factor VIIa (Novo Seven) on thrombocytopenialike conditions in vitro. Semin Hematol 2001, 38:15-20.
229. Kjalke M., Ezban M., Monroe D.M., et al. Highdose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol 2001, 114:114-120.
230. Wilbourn B., Harrison P., Mackie I.J., et al. Activation of platelets in whole blood by recombinant factor VIIa by a thrombin-dependent mechanism. Br J Haematol 2003, 122:651-661.
231. Fattorutto M., Tourreau-Pham S., Mazoyer E., et al. Recombinant activated factor VII decreases bleeding without increasing arterial thrombosis in rabbits. Can J Anaesth 2004, 51:672-679.
232. Almeida A.M., Khair K., Hann I., et al. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 2003, 121:477-481.
233. Gerotziafas G.T., Chakroun T., Depasse F., et al. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thromb Haemost 2004, 91:977-985.
234. Wegert W., Harder S., Bassus S., et al. Plateletdependent thrombin generation assay for monitoring the efficacy of recombinant factor VIIa. Platelets 2005, 16:45-50.
235. Tomokiyo K., Nakatomi Y., Araki T., et al. A novel therapeutic approach combining human plasma-derived factors VIIa and X for haemophiliacs with inhibitors: Evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with factor VIIa alone. Vox Sang 2003, 85:290-299.
236. Sorensen B., Ingerslev J. Thromboelastography and recombinant factor VIIa: Hemophilia and beyond. Semin Hematol 2004, 41:140-144.
237. Yoshioka A., Nishio K., Shima M. Thromboelastogram as a hemostatic monitor during recombinant factor VIIa treatment in hemophilia A patients with inhibitor to factor VIII. Haemostasis 1996, 26(suppl 1):139-142.
238. Carr M.E.Jr., Martin E.J., Kuhn J.G., et al. Monitoring of hemostatic status in four patients being treated with recombinant factor VIIa. Clin Lab 2004, 50:529-538.
239. Kunz D., Kunz W.S., Scott C.S., et al. Automated CD61 immunoplatelet analysis of thrombocytopenic samples. Br J Haematol 2001, 112:584-592.
240. Abe Y., Wada H., Tomatsu H., et al. A simple technique to determine thrombopoiesis level using immature platelet fraction (IPF). Thromb Res. 2005, doi: 10.1016/j.thromres. 2005.09.007.
241. Briggs C., Kunka S., Hart D., et al. Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia. Br J Haematol 2004, 126:93-99.
242. Phillips D.R., Conley P.B., Sinha U., et al. Therapeutic approaches in arterial thrombosis. J Thromb Haemost 2005, 3:1577-1589.
243. Frojmovic M.M. Platelet aggregation in flow: Differential roles for adhesive receptors and ligands. Am Heart J Suppl 1998, 135:5119-5131.
244. Frojmovic M.M., Kasirer-Friede A., Goldsmith H., et al. Surface-secreted von Willebrand factor mediates aggregation of ADP-activated platelets at moderate shear stress: Facilitated by GPIb but controlled by GPIIb-IIIa. Thromb Haemost 1997, 76:568-576.
245. Bonnefoy A., Hantgan R., Legrand C., et al. A model of platelet aggregation involving multiple interactions of thrombospondin-1, fibrinogen and GPIIbIIIa receptor. J Biol Chem 2001, 276:5605-5612.
246. Bonnefoy A., Liu Q., Gray J.W., et al. Platelets in suspension require preactivation to adhere to immobilized fibrinogen. Ann N Y Acad Sci 2001, 936:459-463.
247. Chang H.M., Robertson C.R. Platelet aggregation by laminar shear and Brownian motion. Ann Biomed Eng 1976, 4:151-183.
248. Macaulay I.C., Carr P., Gusnanto A., et al. Platelet genomics and proteomics in human health and disease. J Clin Invest 2005, 115:3370-3377.